Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | EIF2AK2 |
| Gene Name: | EIF2AK2 |
| Protein Full Name: | Interferon-induced, double-stranded RNA-activated |
| Alias: | ADRB2; E2AK2; EC 2.7.11.1; EIF2aK; EIF2AK1; Eukaryotic translation initiation factor 2-alpha kinase 2; Interferon-inducible RNA-dependent protein kinase; Kinase PKR; P1,eIF-2A protein kinase; P1/eIF-2A protein kinase; P68 kinase; PRKR; TIK |
| Mass (Da): | 62094 |
| Number AA: | 551 |
| UniProt ID: | P19525 |
| Locus ID: | 5610 |
| COSMIC ID: | EIF2AK2 |
| Gene location on chromosome: | 2p22-p21 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 20285 |
| Percent of cancer specimens with mutations: | 0.43 |
| Normal role description: | EIF2AK2 is a Serine/Threonine protein kinase that is activated by autophosphorylation after binding to dsRNA (generated during virus infection) in the presence of ATP. Once activated, it can phosphorylate translation initiation factor EIF2S1, which in turn will inhibit protein synthesis. |
| Commentary on involvement of protein in cancer: | The gene is also mutated in 1/171 lung cancer samples and in 2/86 ovarian samples |